top of page

NEWS & INSIGHTS

Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma Funding Activity May 13th-17th 2024

New antibody company launched and more funding events…


Want to get this list of recently funded companies and more data? Fill out a quote request to get more info or set up a call (Quote Request Form)


FIG. 1. Recent Biotech Funding Activity.



Private Funding –


Celaid Therapeutics

💸  Completed series A funding worth a total of 1.2B yen


Uniquity Bio

💸  Launched with $300M capital from Blackstone Life Sciences to Start Phase 2 Clinical Trials in COPD & Asthma with Novel Anti-TSLP Monoclonal Antibody


Lycia Therapeutics

💸  Completed $106.6M series C funding to advance LYTAC extracellular protein degraders pipeline. 


Attovia Therapeutics 

💸  Raised $105m in Series B financing led by Goldman Sachs Alternatives to advance its lead programs and expand pipeline


CinDome Pharma

💸  Announced $40M Series B financing extension to support Deudomperidone Ph 2 envision3D trial. 




Post-IPO/Public Funding –


Erasca 

🏦  Announced pricing for $160M equity offering with J.P. Morgan and BofA Securities as joint book-running managers.


Cassava Sciences

🏦  Raised $125M from equity financing through exercised warrants to fund simufilam development.


RxSight

🏦  Raised $115M in an oversubscribed public offering. 


ADC Therapeutics

🏦  Announced $105M offering and pre-funded warrants.


Reneo Pharmaceuticals

🏦  Proposed merger w/ OnKure which includes $65M private investment in public equity (PIPE) financing. 



---


Article History:

RF, DV, DG (05/21/24)


This article is not investment or legal advice.

Comentarios


bottom of page